Physical activity and exercise outcomes in Huntington's disease (PACE-HD): results of a 12-month trial-within-cohort feasibility study of a physical activity intervention in people with Huntington's disease.

Physical activity is thought to matter for people with Huntington's disease, but there has been no long-term evaluation of whether a structured, therapist-led activity program can actually be tested in this population over a meaningful period. This study asked a feasibility question rather than an effectiveness one: could a 12-month trial comparing a physical activity intervention against a no-contact control group be run within an existing Huntington's disease cohort, across sites in Germany, Spain and the US. Recruitment, retention and adherence all met the study's predefined feasibility targets, and the intervention group showed differences favoring them in fitness, walking endurance and self-reported activity at 12 months.

However, data completeness varied a lot, dropping as low as 19% for some measures at the final assessment, which limits confidence in the outcome findings. The authors frame this as groundwork for a larger, fully-powered trial rather than proof that the intervention works.

If you or someone you know has Huntington's disease, you may have wondered whether staying physically active could help manage the condition over the long term. This study didn't test whether exercise definitely helps, but instead checked whether a longer-term study of exercise support was even practical to run.

People were split into groups: some received no contact between assessments, while others took part in an 18-session physical activity program with a physical therapist over a year, compared to a similar group with no such program. Most people stayed in the study, attended sessions reliably, and reported similar levels of side effects across groups. Those who had the activity program showed some encouraging differences in fitness, walking stamina and self-reported activity levels after a year compared to those who didn't.

However, a lot of information was missing by the end for some measures, so these results should be seen as an early, cautious signal rather than solid evidence that the program improves outcomes. The main achievement here is showing that a bigger, more definitive trial could realistically be conducted.

This is a summary of research, not medical advice. Talk to your own healthcare provider about anything affecting your care.

This was a pilot, cohort-embedded randomized controlled trial (PACE-HD) designed to test feasibility rather than efficacy, using recruitment, retention, adherence, fidelity and safety as predefined progression criteria for a future definitive trial. Of 274 screened and 204 eligible, 116 were enrolled across six Enroll-HD specialist centers (59 cohort, 57 randomized controlled trial), with 12-month retention of 84.7% in the cohort arm and 79.0% in the randomized arm.

The intervention arm received 18 physical therapist-led sessions over 12 months, with 80.5% adherence and high fidelity reported; adverse events were similar between intervention and control groups, though the abstract does not report formal safety analysis beyond this comparison. Clinically, differences favoring the intervention group were observed at 12 months in fitness, walking endurance, and self-reported physical activity, with data completeness above 60% for these specific outcomes. This should be interpreted as exploratory given the pilot design and small sample.

Overall data completeness was inconsistent, ranging from 42.3% to 100% at baseline and as low as 19.2% for some measures at 12 months, a limitation the authors explicitly flag as needing resolution before a larger trial. Motor and functional decline in the untreated cohort matched rates seen in prior natural history studies, supporting the validity of the comparison group even as outcome-level conclusions remain preliminary.